Clinical Trial Update: A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating PTX-200 (triciribine) with cytarabine in refractory or relapsed acute leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• PTX-200 (triciribine)

Snippet

Sponsor: Prescient Therapeutics, Ltd. | Conditions: Acute Leukemia | Phase 1, Phase 2 | Status: COMPLETED